PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
Chong-Sheng QianXiao MaJin WangTing-Jing WangLian BaiHai-Xia ZhouMing-Zhu XuAi-Ning SunDe-Pei WuSong-Bai LiuSheng-Li XuePublished in: Bone marrow transplantation (2020)